COVID-19 is a viral disease that has been declared as pandemic by WHO
COVID-19 (also known as Corona Virus Disease) is a viral disease affecting the respiratory tract of the patients. It is majorly transmitted through contact with respiratory droplets of the patient suffering from the disease. It also spreads when a healthy person touches a surface or object that has the virus on it, then touches their eyes, nose, or mouth. On getting infected, the disease starts developing after 14 days as the virus has an incubation period of 14 days. The major symptoms of COVID-19 include dry cough, tiredness, fever and difficulty breathing (severe cases). Some patients may also suffer from aches and pains, runny nose, nasal congestion, sore throat or diarrhoea.
The disease is caused by an RNA virus that was first isolated in the Bronchoalveolar Lavage Fluid (BALF) of three COVID-19 patients from Wuhan Jinyintan Hospital. The corona virus (CoVs) family is a class of enveloped, positive-sense single-stranded RNA viruses. These viruses are capable of causing respiratory, enteric, hepatic, and neurologic diseases. Nucleic acid test, serologic diagnosis and imaging technology are the major tests that are deployed by the practitioners once the symptom develops in the patients. Chest radiographs produced have similar features on CT images.
For detailed analysis on the COVID-19 – Pipeline Analysis 2020 reports browse through: https://univdatos.com/report/covid-19-pipeline-analysis-2020-for-global-market
Vaccines and drugs both are being developed by the companies in order to manage the disease. Emerging treatment strategies for COVID-19 disease involve the development of small molecule compounds, peptides & proteins and monoclonal antibodies among other which are widely used for the treatment of a variety of diseases. Some of the key players involved in the development of the therapeutics for the treatment of COVID-19 Disease include Ascletis Pharma Inc.; OncoImmune; FUJIFILM Toyama Chemical Co., Ltd.; Sanofi; Gilead Sciences; Incyte Corporation; Hoffmann La Roche; Vanda Pharmaceuticals; Apeiron Biologics and Relief Therapeutics Holdings among others.
COVID-19 Pipeline Analysis Report Segmentation
Products covered by Phase
- Phase III
- Phase II
- Phase I
- Investigational New Drug
Therapeutic Assessment by Stages
- Product Type
- Route of Administration
- Molecule Type
Top Companies Analyzed
- Ascletis Pharma Inc.
- FUJIFILM Toyama Chemical Co., Ltd.
- Gilead Sciences
- Incyte Corporation
- Hoffmann La Roche
- Vanda Pharmaceuticals
- Apeiron Biologics
- Relief Therapeutics Holdings